EP3890731A4 - COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION - Google Patents

COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION Download PDF

Info

Publication number
EP3890731A4
EP3890731A4 EP19892030.8A EP19892030A EP3890731A4 EP 3890731 A4 EP3890731 A4 EP 3890731A4 EP 19892030 A EP19892030 A EP 19892030A EP 3890731 A4 EP3890731 A4 EP 3890731A4
Authority
EP
European Patent Office
Prior art keywords
compounds
treatment
arenavirus infection
arenavirus
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19892030.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3890731A1 (en
Inventor
Eric Brown
Vidyasagar Reddy Gantla
Nadezda Sokolova
Michael Bruno Plewe
Gregory Henkel
Kenneth Mccormack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arisan Therapeutics Inc
Original Assignee
Arisan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arisan Therapeutics Inc filed Critical Arisan Therapeutics Inc
Publication of EP3890731A1 publication Critical patent/EP3890731A1/en
Publication of EP3890731A4 publication Critical patent/EP3890731A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP19892030.8A 2018-12-06 2019-12-03 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION Pending EP3890731A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776390P 2018-12-06 2018-12-06
PCT/US2019/064223 WO2020117794A1 (en) 2018-12-06 2019-12-03 Compounds for the treatment of arenavirus infection

Publications (2)

Publication Number Publication Date
EP3890731A1 EP3890731A1 (en) 2021-10-13
EP3890731A4 true EP3890731A4 (en) 2022-08-17

Family

ID=70975517

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19892030.8A Pending EP3890731A4 (en) 2018-12-06 2019-12-03 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION

Country Status (10)

Country Link
EP (1) EP3890731A4 (https=)
JP (1) JP7675009B2 (https=)
KR (1) KR20210106997A (https=)
CN (1) CN113329750B (https=)
AR (1) AR117228A1 (https=)
AU (1) AU2019393784B2 (https=)
BR (1) BR112021010909A2 (https=)
EA (1) EA202191001A1 (https=)
MX (2) MX2021005234A (https=)
WO (1) WO2020117794A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217490B (zh) * 2023-02-03 2025-09-26 中国人民解放军军事科学院军事医学研究院 一种苯并咪唑类化合物及其制备方法和应用
EP4434972A1 (en) * 2023-03-22 2024-09-25 Eberhard-Karls-Universität Tübingen Atm kinase inhibitors
WO2025137345A1 (en) * 2023-12-20 2025-06-26 Arisan Therapeutics Inc. Crystalline forms of an imidazopyridine derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3675A (en) * 2012-02-17 2016-04-15 Kineta Four Llc Antiviral drugs for treatment of arenavirus infection
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
O'DRISCOLL: "Heavyweight drugs", CHEMISTRY & INDUSTRY, 9 March 2009 (2009-03-09), pages 24 - 26, XP002636700, ISSN: 0009-3068 *
PLEWE ET AL.: "Discovery of a novel highly potent broad-spectrum heterocyclic chemical series of arenavirus cell entry inhibitors", BIOORG. MED. CHEM. LETT., vol. 41, 5 May 2021 (2021-05-05), pages 1 - 9, XP086566088, ISSN: 0960-894X, [retrieved on 20210505], DOI: 10.1016/J.BMCL.2021.127983 *
See also references of WO2020117794A1 *

Also Published As

Publication number Publication date
MX2021005234A (es) 2021-08-11
AU2019393784B2 (en) 2025-06-12
JP2022509763A (ja) 2022-01-24
MX2024013042A (es) 2024-12-06
CA3118765A1 (en) 2020-06-11
EA202191001A1 (ru) 2021-08-16
CN113329750B (zh) 2025-10-17
AU2019393784A1 (en) 2021-05-27
EP3890731A1 (en) 2021-10-13
JP7675009B2 (ja) 2025-05-12
WO2020117794A1 (en) 2020-06-11
CN113329750A (zh) 2021-08-31
BR112021010909A2 (pt) 2021-08-24
KR20210106997A (ko) 2021-08-31
AR117228A1 (es) 2021-07-21

Similar Documents

Publication Publication Date Title
EP3781564A4 (en) Compounds for the treatment of cancer
EP3838239A4 (en) MEDICAL DRESSING
EP3823568A4 (en) GLAUCOMA SURGICAL TREATMENT
AU2019384064B2 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
IL286000A (en) Asketamine for the treatment of depression
IL276482A (en) Compounds for pain management
EP4076461A4 (en) METHODS OF TREATMENT OF SCHIZOPHRENIA
EP3883567B8 (en) Naphthyridinone-aniline compounds for treatment of dermal disorders
EP3890731A4 (en) COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION
EP3813872A4 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
EP3630754B8 (en) Isoindoline-acetylene compounds for the treatment of cancer
EP3846820A4 (en) SULFAMIDE CYCLIC COMPOUNDS FOR THE TREATMENT OF HBV
EP3448377A4 (en) METHODS FOR THE TREATMENT OF AN INFECTION
PL4010302T3 (pl) Mieszanina do obróbki tynku
EP3573634A4 (en) PREPARATION FOR WOUND TREATMENT
EP3733102A4 (en) MEDICAL TREATMENT TOOL
HK40033103A (en) Compounds for the treatment of pain
HK40081993A (en) Compounds for the treatment of covid-19
EP4034125A4 (en) TREATMENT OF DISEASES RELATED TO EXCITOTOXICITY
HK40032171A (en) Combination treatment of sarcoglycanopathies
HK40051477A (en) Heterocyclic compounds for the treatment of epilepsy
HK40075476A (en) Methods of treatment
AU2019903588A0 (en) Treatment of excitotoxicity-related conditions
HK40049516A (en) Kdm1a inhibitors for the treatment of disease
HK40062407A (en) Methods for the treatment of depression

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031418400

Ipc: C07D0249160000

A4 Supplementary search report drawn up and despatched

Effective date: 20220719

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4184 20060101ALI20220713BHEP

Ipc: A61P 31/14 20060101ALI20220713BHEP

Ipc: C07D 487/04 20060101ALI20220713BHEP

Ipc: C07D 471/04 20060101ALI20220713BHEP

Ipc: C07D 249/18 20060101ALI20220713BHEP

Ipc: C07D 249/16 20060101AFI20220713BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231208